FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileShionogi & Co., Ltd.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
SGIOF
Shionogi & Co., Ltd. Stock AnalysisComprehensive stock analysis for Shionogi & Co., Ltd. (SGIOF) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisSGIOF
SGIOF
Shionogi & Co., Ltd.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
SGIOF
  1. Home
  2. Stocks
  3. Shionogi & Co., Ltd.

Shionogi & Co., Ltd.

🇺🇸SGIOF•OTC

Shionogi & Co., Ltd.

🇺🇸SGIOF•OTC
Market cap
$22.07B
P/E ratio
11.01

Your view on SGIOF

Mkt Cap
$22.07B
P/E
11.01
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Shionogi & Co., Ltd.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
CEO
Isao Teshirogi
Headquarters
1-8, Doshomachi 3-chome, Osaka, JP
Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
CEO
Isao Teshirogi
Headquarters
1-8, Doshomachi 3-chome, Osaka, JP
Description

Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Xofluza, an influenza virus drug; and Tivicay for HIV treatment.

It also develops Symproic for opioid-induced constipation treatment; S-120083 for Inflammatory pain; S-010887 for Neuropathic pain; S-117957 for Insomnia; sivopixant for Neuropathic pain, Sleep Apnea Syndrome, and Refractory/unexplainedchronic cough; S-637880 for Neuropathic Low Back Pain; Zuranolone for Depression; SDT-001 for attention-deficit/hyperactivity disorder patients; BPN14770 for Fragile X syndrome and Alzheimer's disease; and S-237648 and S-309309 for Obesity.

In addition, the company develops ADR-001 for Decompensated liver cirrhosis; S-723595 for NASH; S-588410 for Esophageal and Bladder cancer; S-488210 for Head and neck squamouscell carcinoma; S-588210 for Solid tumor; S-222611 for Malignant tumor; S-770108 for Idiopathic pulmonary fibrosis; SR-0379 for Cutaneous ulcer; S-005151 for Stroke and Epidermolysis bullosa; S-531011 for Solid tumor; S-0373 for Spinocerebellar ataxia; and S-600918 and S-217622 for COVID-19, as well as S-555739 for Control of the aggravation of COVID-19.

Further, it offers antibody test kits for COVID-19. Shionogi & Co., Ltd. has collaboration agreements with Nagasaki University, the National Institute of Infectious Diseases, and The Kitasato University to develop antimalarial drugs.

The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan.

Financial Data

Stock Data

Price chart, volume, and trading data.

What moved it

FRC Fair Value Algorithm

What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.

About this section

Fair value for Shionogi & Co., Ltd. from FRC's valuation model, read against the market price. SGIOF last traded at $25.94, 11.0× trailing earnings — the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Shionogi & Co., Ltd.. Starting points for Shionogi & Co., Ltd.: P/E 11.0, EPS $283.22, beta -0.02 — an Drug Manufacturers - Specialty & Generic name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

About this section

Dividend history, yield and payout sustainability for Shionogi & Co., Ltd.. Shionogi & Co., Ltd. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Shionogi & Co., Ltd.. Trailing twelve-month EPS for Shionogi & Co., Ltd. stands at $283.22. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Wall Street analysts· not FRC research
Nov 22, 2026
More →

Earnings per share estimates

Per shareThis quarterDec 2026Next quarterDec 2026This yearYear to Mar 2027Next yearYear to Mar 2028
Average estimateJPY 64.31JPY 64.77JPY 267.75JPY 269.13
Lowest estimateJPY 60.56JPY 64.52JPY 251.97JPY 253.27
Highest estimateJPY 68.14JPY 65.02JPY 287.69JPY 289.17
Number of analysts1123
A year agoJPY 0.351JPY 0.711JPY 242.871—
Growth vs a year ago————

1The year-ago figure includes one-time items, so growth is not shown.

Revenue estimates

TotalThis quarterDec 2026Next quarterDec 2026This yearYear to Mar 2027Next yearYear to Mar 2028
Average estimateJPY 186.65BJPY 186.45BJPY 712.79BJPY 761.04B
Lowest estimateJPY 178.10BJPY 176.76BJPY 693.62BJPY 713.32B
Highest estimateJPY 194.97BJPY 196.65BJPY 739.43BJPY 818.92B
Number of analysts551011
A year agoJPY 139.87BJPY 162.13BJPY 502.82B—
Growth vs a year ago+33.4%+15.0%+41.8%—

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Shionogi & Co., Ltd.. Shionogi & Co., Ltd. has reported as a listed company since 2018. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold SGIOF12 companies
More Drug Manufacturers - Specialty & Generic companies
TickerTypeCompanySectorExchangeMkt cap
RDDTFRadient Technologies Inc.HealthcareOTC$5,399
RDHLRedHill Biopharma Ltd.HealthcareNASDAQ$883,143
RDYDr. Reddy's Laboratories LimitedHealthcareNYSE$12.4B
REZNFStreet Capital Inc.HealthcareOTC$1.4M
RGCRegencell Bioscience Holdings LimitedHealthcareNASDAQ$2.1B
RGT.AXArgent BioPharma LimitedHealthcareASX—
RLBDReal Brands, Inc.HealthcareOTC$269,064
RMTIRockwell Medical, Inc.HealthcareNASDAQ$23.5M
ROMJ.VRubicon Organics Inc.HealthcareTSXV$22.0M
ROMJFRubicon Organics Inc.HealthcareOTC$24.1M
RVV.CNRevive Therapeutics Ltd.HealthcareCNQ$6.5M
RVVQFRavenQuest BioMed Inc.HealthcareOTC$1,236
Ownership & News

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Shionogi & Co., Ltd.. Coverage tracks Shionogi & Co., Ltd. within Drug Manufacturers - Specialty & Generic (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Shionogi & Co., Ltd.

SGIOF AnalysisFair
Past
3
Growth
1
Health
4
Profit
0
Value
3